{"nctId":"NCT00411645","briefTitle":"Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients","startDateStruct":{"date":"2006-12-13","type":"ACTUAL"},"conditions":["Cytomegalovirus Infections"],"count":681,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: maribavir"]},{"label":"B","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"maribavir","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Allogeneic stem cell transplant recipient\n* Recipient or donor CMV seropositive\n* Have transplant engraftment\n* Able to swallow tablets\n\nExclusion Criteria:\n\n* CMV organ disease\n* HIV infection\n* Use of other anti-CMV therapy post-transplant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation","description":"All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever \\>/=38 °C on \\>/=2 occasions \\>/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell \\[WBC\\] count \\<3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was \\>4000/mm3) \\>/=24 hours apart, atypical lymphocytosis \\>/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With CMV Infection or EC-confirmed CMV Disease Within 6 Months Post-transplant","description":"All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever \\>/=38 °C on \\>/=2 occasions \\>/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell \\[WBC\\] count \\<3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was \\>4000/mm3) \\>/=24 hours apart, atypical lymphocytosis \\>/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"143","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"152","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"183","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"172","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of CMV Infection or EC-confirmed CMV Disease Within 6 Months Post- Transplantation","description":"All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease) were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay or (2) CMV DNA polymerase chain reaction (PCR). CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever \\>/=38 °C on \\>/=2 occasions \\>/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell \\[WBC\\] count \\<3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was \\>4000/mm3) \\>/=24 hours apart, atypical lymphocytosis \\>/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Investigator-determined CMV Disease","description":"CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever \\>/=38 °C on \\>/=2 occasions \\>/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell \\[WBC\\] count \\<3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was \\>4000/mm3) \\>/=24 hours apart, atypical lymphocytosis \\>/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With CMV Infection or EC-confirmed CMV Disease Within 100 Days Post-Transplantation","description":"All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever \\>/=38 °C on \\>/=2 occasions \\>/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell \\[WBC\\] count \\<3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was \\>4000/mm3) \\>/=24 hours apart, atypical lymphocytosis \\>/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"157","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"139","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With EC-confirmed CMV Disease Within 12 Months Post-Transplantation","description":"All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever \\>/=38 °C on \\>/=2 occasions \\>/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell \\[WBC\\] count \\<3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was \\>4000/mm3) \\>/=24 hours apart, atypical lymphocytosis \\>/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With Acute Graft-Versus-Host Disease (GVHD)","description":"Analysis of acute GVHD was based on reported adverse events that mapped to the relevant MedDRA dictionary terms for acute GVHD. The percentage reported is for the occurrence of any grade of acute GVHD.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With Chronic Graft-Versus-Host Disease (GVHD)","description":"Analysis of chronic GVHD was based on reported adverse events that mapped to the relevant MedDRA dictionary terms for chronic GVHD. The percentage reported is for the occurrence of any grade of chronic GVHD.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Died Within 12 Months Post-Transplantation","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"139","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Maribavir During Treatment","description":"Pharmacokinetic (PK) profile sampling was performed to evaluate plasma concentrations of Maribavir. During the study drug administration period, blood samples for this purpose were collected on Day 7 (Week 1) and at Week 4. Every effort was made to ensure that doses were administered 12 hours apart on the day before and on the day of PK sampling. Permissible assessment windows for PK profile sampling purposes were +/- 3 days and +/- 5 days for the 1- and 4- week samples, respectively. Samples were analyzed by a validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method. The validated lower limit of quantitation (LLOQ) in plasma was 0.2 μg/mL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":"2.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.19","spread":"1.99"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Maribavir Metabolite VP 44469 During Treatment","description":"Pharmacokinetic (PK) profile sampling was performed to evaluate plasma concentrations of VP 44469, a metabolite of Maribavir. During the study drug administration period, blood samples for this purpose were collected on Day 7 (Week 1) and at Week 4. Every effort was made to ensure that doses were administered 12 hours apart on the day before and on the day of PK sampling. Permissible assessment windows for PK profile sampling purposes were +/- 3 days and +/- 5 days for the 1- and 4- week samples, respectively. Samples were analyzed by a validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method. The validated lower limit of quantitation (LLOQ) in plasma was 0.2 μg/mL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"0.47"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":98,"n":223},"commonTop":["Acute Graft Versus Host Disease","Diarrhoea","Nausea","Fatigue","Rash"]}}}